Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $28.00 at Jefferies Financial Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by equities researchers at Jefferies Financial Group from $77.00 to $28.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 88.55% from the company’s previous close.

RARE has been the subject of several other research reports. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald reduced their price objective on shares of Ultragenyx Pharmaceutical from $103.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday. William Blair reissued a “market perform” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday. Finally, Robert W. Baird restated a “neutral” rating and set a $16.00 target price (down from $40.00) on shares of Ultragenyx Pharmaceutical in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $37.53.

Ultragenyx Pharmaceutical Trading Down 44.0%

Shares of NASDAQ:RARE traded down $11.68 during trading on Thursday, reaching $14.85. The company’s stock had a trading volume of 27,027,359 shares, compared to its average volume of 2,391,737. The stock has a market capitalization of $1.46 billion, a PE ratio of -2.54 and a beta of 0.31. Ultragenyx Pharmaceutical has a 12 month low of $13.81 and a 12 month high of $39.89. The firm’s 50 day simple moving average is $28.36 and its two-hundred day simple moving average is $25.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company’s quarterly revenue was up 28.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.17) EPS. Research analysts anticipate that Ultragenyx Pharmaceutical will post -3.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director owned 21,095 shares in the company, valued at approximately $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of RARE. Parallel Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,440 shares in the last quarter. Leonteq Securities AG boosted its stake in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,333 shares in the last quarter. Versant Capital Management Inc boosted its stake in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares in the last quarter. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $39,000. Finally, EverSource Wealth Advisors LLC grew its position in Ultragenyx Pharmaceutical by 573.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx’s commercial business remains a potential support for the stock, and analysts noted that the company may still have value through its marketed rare-disease therapies and other pipeline programs. Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn’t Giving Up Yet
• Positive Sentiment: Some analysts retained bullish ratings despite lowering their valuations: Citi, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright continued to rate the shares Buy or Overweight, with targets still above the current trading level. Why Wall Street Isn’t Giving Up Yet
• Positive Sentiment: Unusually high call-option activity and speculation that Ultragenyx could become an acquisition target provide potential, though highly speculative, sources of investor interest.
• Neutral Sentiment: Ultragenyx may evaluate “significant” cost reductions and reconsider the future of its Angelman syndrome program, potentially preserving cash but signaling a smaller development footprint. Ultragenyx to Weigh Significant Cost Cuts
• Neutral Sentiment: The company recently highlighted a successful 96-week randomized trial of GENGLYCOS (DTX401), offering a positive data point outside the failed Angelman program.
• Negative Sentiment: Phase 3 ASPPIRE failed to meet both its primary endpoint—change in Bayley-4 cognitive raw score—and the key secondary endpoint, the Multidomain Responder Index. The results cast substantial doubt on apazunersen’s development and commercial prospects. Ultragenyx Announces Phase 3 ASPPIRE Results
• Negative Sentiment: Multiple firms cut price targets and/or downgraded the stock, including Bank of America, JPMorgan, Wells Fargo, Evercore, Baird and Wedbush, reflecting sharply reduced estimates after the trial failure. Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Late-Stage Trial

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.